ARDSのチャート
ARDSの企業情報
| symbol | ARDS |
|---|---|
| 会社名 | Aridis Pharmaceuticals Inc （アリディス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Aridis Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies such as rise in drug resistance short duration of response negative impact on the human microbiome and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections primarily hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Its lead product candidate AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M mAb targeting P. aeruginosa serotype O11. アリディス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、感染症に対する免疫療法の開発・商業化に従事する。完全ヒトモノクロナ―ル抗体を用いて、薬物耐性や短い薬効時間、ヒトのミクロバイオ―ムへの悪影響などの治療の欠点を克服するように設計され、同社の差別化抗体発見プラットフォ―ムを使用する。本社所在地はカリフォルニア州サンノゼ。 Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ?PEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. |
| 本社所在地 | 5941 Optical Ct. San Jose CA 95138 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 408-385-1742 |
| 設立年月日 | 2003年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | 30人 |
| url | www.aridispharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ards |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -21.68200 |
| 終値（lastsale） | 12.8254 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額（百万ドル） 100.48690 |
| 売上高 | 売上高（百万ドル） 1.16000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 161.21890 |
| 当期純利益 | 当期純利益（百万ドル） -22.02800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aridis Pharmaceuticals Inc revenues increased from $44K to $344K. Net loss applicable to common stockholders decreased 35% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of warrant liabilit increase from $4.6M (expense) to $3M (income). |
ARDSのテクニカル分析
ARDSのニュース
AstraZeneca Axes Pneumonia Drug Pact With Aridis 2023/03/29 17:17:26 Benzinga
AstraZeneca plc (NASDAQ: AZN ) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS ). With the license terminated for AR-320 (suvratoxumab), the ongoing AR-320-003 Phase 3 clinical study must be put on hold, the company said in an SEC filing. The SAATELLITE-2 trial enrolled the first patient in … Full story available on Benzinga.com
Why Aridis Pharmaceuticals Shares Are Diving 2023/03/14 15:24:52 Benzinga
Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) shares are trading lower by 23.34% to $0.42 Tuesday morning after the company announced a $2.28 million registered direct offering. The company has entered a definitive agreement for the … Full story available on Benzinga.com
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday''s Mid-Day Session 2023/03/13 17:22:23 Benzinga
Gainers Provention Bio, Inc. (NASDAQ: PRVB ) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. Hycroft Mining Holding Corporation (NASDAQ: HYMC ) surged 41.6% to $0.4390. Calliditas Therapeutics AB (NASDAQ: CALT ) shares gained 33.7% to $22.73 after the company announced the primary endpoint was successfully met in the Phase 2 NefIgArd trial evaluating Nefecon in IgA nephropathy. Clearmind Medicine Inc. (NASDAQ: CMND ) gained 31.7% to $4.53. Cipher Mining Inc. (NASDAQ: CIFR ) rose 30.2% to $1.7195. EUDA Health Holdings Limited (NASDAQ: EUDA ) gained 30% to $2.62. ZIM Integrated Shipping Services Ltd. (NYSE: ZIM ) surged 23.7% to $24.20 after the company reported a fourth-quarter FY22 sales decline of 37% year-on-year to $2.19 billion, beating the consensus of $2.11 billion. Austin Gold Corp. (NYSE: AUST ) rose 22.2% to $1.10 Iris Energy Limited (NASDAQ: IREN ) rose 22% to $3.16. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS ) gained 20% to $0.5530 after the company announced the primary and secondary endpoints were met in the Phase 2a study of AR-501 in cystic fibrosis patients.
Why Aridis Pharmaceuticals Shares Are Soaring Today 2023/03/13 13:15:27 Benzinga
Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections. The study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol and was conducted with funding support from the Cystic Fibrosis Foundation. AR-501 is being developed as a once-per-week … Full story available on Benzinga.com
Aridis Skyrockets on Impressive Data In Cystic Fibrosis 2023/03/13 13:14:50 TipRanks
Shares of biopharmaceutical company Aridis Pharmaceuticals (NASDAQ:ARDS) are soaring higher today after the company announced preliminary top-line …
Aridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82M 2022/05/16 20:34:55 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q1 GAAP EPS of -$0.44 beats by $0.07.Revenue of $1.18M misses by $0.82M.
Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update 2022/05/16 20:05:00 PR Newswire
Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening…
Aridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33M 2022/04/01 11:24:43 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q4 GAAP EPS of -$0.92 misses by $0.59.Revenue of $0.57M misses by $1.33M.
Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update 2022/03/31 22:04:00 PR Newswire
Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a…
Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study 2022/02/17 16:41:34 Benzinga
Aridis Pharmaceuticals Inc''s (NASDAQ: ARDS ) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant . Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, … Full story available on Benzinga.com
Aridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82M 2022/05/16 20:34:55 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q1 GAAP EPS of -$0.44 beats by $0.07.Revenue of $1.18M misses by $0.82M.
Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update 2022/05/16 20:05:00 PR Newswire
Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening…
Aridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33M 2022/04/01 11:24:43 Seeking Alpha
Aridis Pharmaceuticals press release (ARDS): Q4 GAAP EPS of -$0.92 misses by $0.59.Revenue of $0.57M misses by $1.33M.
Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update 2022/03/31 22:04:00 PR Newswire
Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a…
Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study 2022/02/17 16:41:34 Benzinga
Aridis Pharmaceuticals Inc''s (NASDAQ: ARDS ) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant . Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, … Full story available on Benzinga.com